Literature DB >> 16305592

Effects of grapefruit juice on the pharmacokinetics of acebutolol.

Jari J Lilja1, Kari Raaska, Pertti J Neuvonen.   

Abstract

AIMS: We aimed to investigate effects of grapefruit juice on acebutolol pharmacokinetics.
METHODS: In a randomized cross-over study, 10 healthy subjects ingested 200 mL grapefruit juice or water three times daily for 3 days and twice on day 4. On day 3, each subject ingested 400 mg acebutolol with grapefruit juice or water. The concentrations of acebutolol and its metabolite diacetolol were measured in plasma and urine up to 33 h.
RESULTS: Grapefruit juice decreased the peak plasma concentration (Cmax) of acebutolol by 19% from 872 +/- 207 ng mL(-1) to 706 +/- 140 ng mL(-1) (95% CI on the difference -306, -26.4; P < 0.05), and the area under the concentration time curve (AUC(0-33 h)) by 7%, from 4498 +/- 939 ng mL(-1) h to 4182 +/- 915 ng mL(-1) h (95% CI -609, -23.0; P < 0.05). The half-life (t1/2) of acebutolol prolonged from 4.0 to 5.1 h (P < 0.05). The time to peak concentration and the amount of acebutolol excreted into urine (Ae) were unchanged. The Cmax, AUC(0-33 h), and Ae of diacetolol were decreased by 24% (P < 0.05), 18% (P < 0.05), and 20% (P < 0.01), respectively, by grapefruit juice.
CONCLUSION: Grapefruit juice caused a small decrease in the plasma concentrations of acebutolol and diacetolol by interfering with gastrointestinal absorption. The interaction between the grapefruit juice and acebutolol is unlikely to be of clinical significance in most of the patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305592      PMCID: PMC1884877          DOI: 10.1111/j.1365-2125.2005.02489.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells.

Authors:  H Takanaga; A Ohnishi; H Matsuo; Y Sawada
Journal:  Biol Pharm Bull       Date:  1998-10       Impact factor: 2.233

2.  Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Authors:  George K Dresser; David G Bailey; Brenda F Leake; Ute I Schwarz; Paul A Dawson; David J Freeman; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2002-01       Impact factor: 6.875

3.  Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.

Authors:  V A Eagling; L Profit; D J Back
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

4.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

Authors:  M Cvetkovic; B Leake; M F Fromm; G R Wilkinson; R B Kim
Journal:  Drug Metab Dispos       Date:  1999-08       Impact factor: 3.922

5.  Grapefruit juice ingestion significantly reduces talinolol bioavailability.

Authors:  Ute I Schwarz; Diana Seemann; Reinhard Oertel; Stephan Miehlke; Eberhard Kuhlisch; Martin F Fromm; Richard B Kim; David G Bailey; Wilhelm Kirch
Journal:  Clin Pharmacol Ther       Date:  2005-04       Impact factor: 6.875

6.  Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.

Authors:  George K Dresser; Richard B Kim; David G Bailey
Journal:  Clin Pharmacol Ther       Date:  2005-03       Impact factor: 6.875

7.  P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.

Authors:  H Spahn-Langguth; G Baktir; A Radschuweit; A Okyar; B Terhaag; P Ader; A Hanafy; P Langguth
Journal:  Int J Clin Pharmacol Ther       Date:  1998-01       Impact factor: 1.366

8.  Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.

Authors:  K S Lown; D G Bailey; R J Fontana; S K Janardan; C H Adair; L A Fortlage; M B Brown; W Guo; P B Watkins
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

9.  Effect of grapefruit juice on digoxin pharmacokinetics in humans.

Authors:  L Becquemont; C Verstuyft; R Kerb; U Brinkmann; M Lebot; P Jaillon; C Funck-Brentano
Journal:  Clin Pharmacol Ther       Date:  2001-10       Impact factor: 6.875

10.  Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.

Authors:  J J Lilja; K T Kivistö; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1998-11       Impact factor: 6.875

View more
  7 in total

Review 1.  Influence of dietary substances on intestinal drug metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Curr Drug Metab       Date:  2010-11       Impact factor: 3.731

Review 2.  Fruit juice inhibition of uptake transport: a new type of food-drug interaction.

Authors:  David G Bailey
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology.

Authors:  Le Sun; Jin Sun; Zhonggui He
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

Review 4.  The effect of grapefruit juice on drug disposition.

Authors:  Michael J Hanley; Paul Cancalon; Wilbur W Widmer; David J Greenblatt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01-22       Impact factor: 4.481

Review 5.  Grapefruit-drug interactions.

Authors:  Kay Seden; Laura Dickinson; Saye Khoo; David Back
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

6.  Apple juice greatly reduces systemic exposure to atenolol.

Authors:  Hyewon Jeon; In-Jin Jang; SeungHwan Lee; Kyoichi Ohashi; Tsutomu Kotegawa; Ichiro Ieiri; Joo-Youn Cho; Seo Hyun Yoon; Sang-Goo Shin; Kyung-Sang Yu; Kyoung Soo Lim
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

7.  Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  Mol Pharm       Date:  2014-03-28       Impact factor: 4.939

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.